Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low‐Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison

BACKGROUND. Daratumumab (a human CD38‐directed monoclonal antibody) and pomalidomide (an immunomodulatory drug) plus dexamethasone are both relatively new treatment options for patients with heavily pretreated multiple myeloma. A matching adjusted indirect comparison (MAIC) was used to compare absol...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Van Sanden, Suzy, Ito, Tetsuro, Diels, Joris, Vogel, Martin, Belch, Andrew, Oriol, Albert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2017
Gaiak:
Academia‐Pharma Intersect: Hematologic Malignancies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5905688/
https://ncbi.nlm.nih.gov/pubmed/29192016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0103
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak